Sarepta's Gene Therapy Under FDA Scrutiny Amid Safety Concerns
TL;DR Summary
Shares of Sarepta Therapeutics dropped over 30% after the FDA indicated it might halt shipments of its gene therapy Elevidys due to safety concerns and ongoing investigations into patient deaths, casting doubt on the future of the treatment for Duchenne Muscular Dystrophy.
- Sarepta shares plunge 30% as future of its gene therapy appears at risk CNBC
- Exclusive: US FDA to request Sarepta to stop all shipments of gene therapy Elevidys, source says Reuters
- FDA Is Investigating If Sarepta’s Gene Therapy Should Stay on Market Bloomberg.com
- Patient dies in Sarepta gene therapy trial, adding to safety concerns STAT
- Sarepta (SRPT) Jumps Nearly 20% on Corporate Restructuring Yahoo Finance
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 2 min read
Condensed
88%
355 → 42 words
Want the full story? Read the original article
Read on CNBC